New molecular targeted therapies in thyroid cancer

Anti-Cancer Drugs

Volumn 17, Issue 8, 2006, Pages 869-879

  Milano, Amalia ^a   Chiofalo, Maria G ^a   Basile, Maria ^a   Salzano De Luna, Antonella ^a   Pezzullo, Luciano ^a   Caponigro, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

New drugs; Targeted therapy; Thyroid carcinoma

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; DEPSIPEPTIDE; DOCETAXEL; DOXORUBICIN; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IRINOTECAN; LGD 1550; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; PANITUMUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; RETINOL DERIVATIVE; ROFECOXIB; SORAFENIB; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; VORINOSTAT;

ACNE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE RET; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA; THYROID CANCER; THYROID CARCINOMA; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL MEMBRANE; CELL NUCLEUS; CYTOPLASM; HUMANS; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 33748452681     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000224449.16329.c5     Document Type: Review

References (139)

1. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309:937-941.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338:297-306.
3. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155-2160.
4. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70:405-407.
5. Weber T, Shilling T, Buchler MW. Thyroid carcinoma. Curr Opin Oncol 2006; 18:30-35.
6. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994; 73:432-436.
7. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET normal and abnormal functions. Endocrinology 2004; 145:5448-5451.
8. Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T, et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer 2005; 92:1110-1116.
9. Challeton C, Bounacer A, Du Villard JA, Caillou B, De Vathaire F, Monier R, et al. Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene 1995; 11:601-603.
10. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88:5399-5404.
11. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993; 91:179-184.
12. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992; 52:1369-1371.
13. - symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86:3430-3435.
14. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13:477-483.
15. Schmutzler C, Brtko J, Bienert K, Kohrle J. Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived there from. Exp Clin Endocrinol Diabetes 1996; 104 (Suppl):S16-S19.
16. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000; 60:5117-5124.
17. Ellis LM, Liu W, Fan F, Reinmuth N, Shaheen RM, Jung YD, et al. Role of angiogenesis inhibitors in cancer treatment. Oncology 2001; 15 (Suppl):S39-S46.
18. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-674.
19. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246:1309-1312.
20. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995; 129:895-898.
21. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and flt-1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269:26988-26995.
22. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-2970.
23. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993; 4:121-133.
24. Gille J, Swerlick RA, Caughman SW. Transforming growth factor-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP2-dependent DNA binding and transactivation. EMBO J 1997; 16:750-759.
25. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10:784-793.
26. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62:7284-7290.
27. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004; 36:6056-6063.
28. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret protooncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cells 1990; 60:557-563.
29. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, et al. Molecular characterization of RET/PTC3: a novel rearranged version of the RET protoncogene in a human thyroid papillary carcinomas. Oncogene 1994; 9:509-516.
30. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, et al. Ret oncogenes activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992; 89:1517-1522.
31. Fugazzola L, Pilotti S, Pinchera A, Vorontsova TV, Mondellini P, Bongarzone I, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 1995; 55:5617-5620.
32. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M et al. High prevalence of activating RET protoncogene rearrangements in thyroid tumors from patients who had received external radiation. Oncogene 1997; 15:1263-1273.
33. Vidal M, Wells S, Ryan A, Cagan R. ZD 6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 2005; 65:3538-3541.
34. Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005; 16:1391-1397.
35. Jackson E, Esparza-Coss E, Bankson A, Coxon A, Patel V, Polverino T, et al. The effect of AMG 706, a novel multi-kinase inhibitor, on vascular permeability and blood flow as assessed by dynamic contrast enhanced magnetic resonance imaging in an in vivo preclinical tumor model. Proc Am Soc Clin Oncol 2005; 23:225s (abstr 3134).
36. Rosen L, Kurzrock R, Jackson E, Wathen L, Parson M, Eschenberget M, et al. Safety and pharmacokinetics of AMG706 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2005; 23:195s (abstr 3013).
37. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinolgy 2006; 145:1031-1038.
38. Duh QY, Gum ET, Gerend PL, Raper SE, Clark OH. Epidermal growth factor receptors in normal and neoplastic thyroid tissues. Surgery 1985; 98:1000-1007.
39. Gorgoulis V, Aninos D, Priftis C, Evagelopoulou C, Karameris A, Kanavaros P, et al. Expression of epidermal growth factor, transforming growth factor-α and epidermal growth factor receptor in thyroid tumors. In Vivo 1992; 6:291-296.
40. Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB3 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995; 76:1643-1654.
41. Chen BK, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Liang SB, et al. Co-expression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlates with lymph-node metastasis, tumor size and clinicopathologic stage. Int J Oncol 1999; 15:893-898.
42. Bechtner G, Schopohl D, Rafferzeder M, Gartner R, Welsch U. Stimulation of thyroid cell proliferation by epidermal growth factor is different from cell growth induced by thyrotropin orinsulin-like growth factor I. Eur J Endocrinol 1996; 134:639-648.
43. Akslen LA, Myking AO, Salvesen H, Varhaug JE. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer 1993; 68:808-812.
44. Di Carlo A, Mariano A, Pisano G, Parmeggiani U, Beguinot L, Macchia V, et al. Epidermal growth factor receptor and thyrotropin response in human tissues. J Endocrinol Invest 1990; 13:293-299.
45. Ensinger C, Spizzo G, Moser P, Tschoerner I, Prommegger R, Gabriel M, et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carinomas. Ann N Y Acad Sci 2004; 1030:69-77.
46. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-5754.
47. Sirotnak FM. Studies with ZD1839 in preclinical models. Semin Oncol 2003; 30 (Suppl):S12-S20.
48. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Vigano L, et al. Inhibition of proliferation and induction of apoptosis in breast cancer cells by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa) is independent of EGFR expression level. J Cell Physiol 2004; 198:259-268.
49. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 15:2237-2246.
50. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
51. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004; 10:8594-8602.
52. Calvo E, Rowinsky EK. Clinical experience with monoclonal antibodies to epidermal growth factor receptor. Curr Oncol Rep 2005; 7:96-103.
53. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
54. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006; 12:600-607.
55. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Nebiyou Bekele B, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 2005; 4:632-640.
56. Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002; 62:1077-1082.
57. Vitagliano D, Carlomagno F, Motti ML, Viglietto G, Nikiforov YE, Nikiforova MN, et al. Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res 2004; 64:3823-3829.
58. Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999; 274:8328-8334.
59. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6:4064-4068.
60. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89:2637-2645.
61. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999; 5:2018-2024.
62. Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000; 6:519-525.
63. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, et al. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5:1001-1005.
64. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002; 62:1676-1681.
65. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89:589-596.
66. Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey TJ 3rd. Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 2002; 87:358-363.
67. Nose F, Ichikawa T, Fujiwara M, Okayasu I. Up-regulation of cyclooxygenase-2 expression in lymphocytic thyroiditis and thyroid tumors: significant correlation with inducible nitric oxide synthase. Am J Clin Pathol 2002; 117:546-551.
68. Cornetta AJ, Russell JP, Cunnane M, Keane WM, Rothstein JL. Cyclooxygenase-2 expression in human thyroid carcinoma and Hashimoto's thyroiditis. Laryngoscope 2002; 112:238-242.
69. Ito Y, Yoshida H, Nakano K, Takamura Y, Miya A, Kobayashi K, et al. Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology 2003; 42:492-497.
70. Kajita S, Ruebel KH, Casey MB, Nakamura N, Lloyd RV. Role of COX-2, thromboxane A2 synthase and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Mod Pathol 2005; 18:221-227.
71. Wang D, DuBois RN. Cyclooxigenase-2 derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A 2004; 101:415-416.
72. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, et al. Combination of a selective COX-2 inhibitor with EGFR tyrosine kinase inhibitor ZD 1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenetic effect. Clin Cancer Res 2003; 9:1566-1572.
73. Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res 2005; 11:1268-1276.
74. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, Vignali C, et al. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 2005; 90:5754-5760.
75. Manie S, Santoro M, Fusco A, Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 2001; 17:580-589.
76. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003; 120:71-77.
77. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63:1454-1457.
78. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR. The ins and outs of Raf kinases. Trends Biochem Sci 1994; 19:474-480.
79. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
80. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinomas. J Natl Cancer Inst 2003; 95:625-627.
81. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PRTC. Oncogene 2003; 22:4578-4580.
82. Schlessinger J. Cell signaling receptor tyrosine kinases. Cell 2000; 103:211-215.
83. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 4:1068-1081.
84. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88:4393-4397.
85. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63:4561-4567.
86. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45:818-821.
87. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol 2004; 61:239-243.
88. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, et al. BRAF (V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89:2414-2420.
89. Bollag G, Freeman S, Lyons JF, Post LE. Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 2003; 4:1436-1441.
90. Dumas J, Smith RA, Lowinger T. Recent developments in the discovery of protein kinase inhibitors from the urea class. Curr Opin Drug Discov Dev 2004; 7:600-616.
91. Xing M. B-RAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12:245-262.
92. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004; 23:6292-6298.
93. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855-867.
94. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
95. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006; 12:1623-1629.
96. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: is rash associated with treatment outcome? Eur J Cancer 2006; 42:548-556.
97. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005; 23:6771-6790.
98. Sebolt-Leopold JS. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des 2004; 10:1907-1914.
99. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999; 5:810-816.
100. Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 2003; 22:4406-4412.
101. Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK-inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23:5281-5293.
102. Rinehart J, Adjei AA, LoRusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK-inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22:4456-4462.
103. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-ABL. Trends Cell Biol 1999; 9:179-186.
104. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, et al. Ataxia telangiectasia mutant protein activates c-ABL tyrosine kinase in response to ionizing radiation. Nature 1997; 387:516-519.
105. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, et al. Interaction between ATM protein and c-ABL in response to DNA damage. Nature 1997; 387:520-523.
106. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, et al. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003; 88:1889-1896.
107. Whang YE, Tran C, Henderson C, Syljuasen RG, Rozengurt N, McBride WH, et al. c-ABL is required for development and optimal cell proliferation in the context of p53 deficiency. Proc Natl Acad Sci U S A 2000; 97:5486-5491.
108. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994-1004.
109. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370:737-749.
110. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2004; 101:18030-18035.
111. Marks P, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92:1210-1216.
112. Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2005; 90:1383-1389.
113. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968.I. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor activity. J Antibiot 1994; 47:301-310.
114. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996; 5:245-253.
115. Della Ragione F, Criniti V, Della Pietra V, Borriello A, Oliva A, Indaco S, et al. Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett 2001; 499:199-204.
116. Imanishi R, Ohtsuru A, Iwamatsu M, Iioka T, Namba H, Seto S, et al. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J Clin Endocrinol Metab 2002; 87:4821-4824.
117. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no 968, on H-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 1994; 58:1579-1583.
118. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J et al. Phase I trial of the hystone deacetylase inhibitor, depsipeptide (FR901228, NSC 630175), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-728.
119. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999; 59:4392-4399.
120. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, et al. Suberoylanide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60:5165-5170.
121. Qiu L, Kelso MJ, Hansen C, West ML, Fairlie DP, Parsons PG. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer 1999; 80:1252-1258.
122. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, et al. Novel hystone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 2005; 11:3958-3965.
123. Gui Cy, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21waf1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004; 5:1241-1246.
124. L, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18:7016-7025.
125. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9:3578-3588.
126. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1:181-193.
127. Wolf G. A history of vitamin A and retinoids. FASEB J 1996; 10:1102-1107.
128. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998; 22:569-574.
129. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cells lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 2004; 89:272-280.
130. Rastinejad F. Retinoid X receptor and its partners in the nuclear receptor family. Curr Opin Struct Biol 2001; 11:33-38.
131. Soignet SL, Miller VA, Pfister DG, Bienvenu BJ, Ho R, Parker BA, et al. Initial clinical trial of a high-affinity retinoic acid receptor ligand (LGD1550). Clin Cancer Res 2000; 6:1731-1735.
132. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. Ligand binding and co-activator assembly of the peroxisome proliferators- activated receptor γ. Nature 1998; 395:137-143.
133. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405:421-424.
134. Martelli ML, Iuliano R, Pera I, Sama' I, Monaco C, Cammarota S, et al. Inhibitory effects of peroxisome proliferators-activated receptor γ on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002; 87:4728-4735.
135. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferators-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86:2170-2177.
136. Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome prolifertor-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999; 55:932-943.
137. Murphy GJ, Holder JC. PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000; 21:469-474.
138. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferators-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000; 92:418-423.
139. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugne BR. Retinoid X receptor-γ and peroxisome proliferators-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 2004; 3:1011-1020.